MBX Latest News, Press Relases and Analysis

All

Press Releases

10 hours ago - By: The Motley Fool - Mentions: MDGL CGEM RNA TRVI ...

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

2 days ago - By: Zacks Investment Research

How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%

2 days ago - By: Zacks Investment Research - Mentions: UNH JNJ PWR STX ...

Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus

6 days ago - By: The Motley Fool - Mentions: MDGL CGEM RNA TRVI ...

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

2 months ago - By: Investor's Business Daily

MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise

2 months ago - By: Stocktwits

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study

16 days ago - By: MBX Biosciences, Inc.

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

19 days ago - By: Zacks Investment Research

Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High?

a month ago - By: MBX Biosciences, Inc.

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

a month ago - By: Benzinga - Mentions: Q TWST ANTA PXED

This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

a month ago - By: Zacks Investment Research

Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet

4 months ago - By: Benzinga

A Glimpse of MBX Biosciences's Earnings Potential

a month ago - By: MBX Biosciences, Inc.

MBX Biosciences to Participate in November Investor Conferences

2 months ago - By: MBX Biosciences, Inc.

MBX Biosciences Announces Pricing of Upsized Public Offering

2 months ago - By: MBX Biosciences, Inc.

MBX Biosciences Announces Proposed Public Offering

2 months ago - By: MBX Biosciences, Inc.

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

3 months ago - By: MBX Biosciences, Inc.

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

3 months ago - By: MBX Biosciences, Inc.

MBX BIOSCIENCES INC (MBX) Stock News

MBX Latest News, Press Relases and Analysis

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%

Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High?

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet

A Glimpse of MBX Biosciences's Earnings Potential

MBX Biosciences to Participate in November Investor Conferences

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity